EcoDrugPlus

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSAPEG00000015273
Gene Symbol: PDE5AB
2 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSAPEG00000020507
Gene Symbol: PDE7A
1 Cross references
215 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSAPEG00000008211
Gene Symbol: PDE7B
2 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSAPEG00000024113
Gene Symbol: PDE9A
1 Cross references
192 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSAPEG00000007075
Gene Symbol: PIK3R3
1 Cross references
188 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSAPEG00000002826
Gene Symbol: PIK3R3
1 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSAPEG00000001053
Gene Symbol: PIK3R5
1 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSAPEG00000022087
Gene Symbol: PIK3R1
1 Cross references
197 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSAPEG00000002394
Gene Symbol: PIK3R1
1 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSAPEG00000016119
Gene Symbol: PIK3R2
1 Cross references
190 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSAPEG00000012275
Gene Symbol: PLA2G10
1 Cross references
233 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSAPEG00000015345
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).